Search information
ArriVent BioPharma, Inc. Common Stock
Companies
"Incentive"
Keywords
Tables in SEC filings
Source
| | | | | | |
| | Year Ended December 31, | ||||
| 2023 | 2022 | ||||
Research and development | | $ | 432 | | $ | 215 |
General and administrative | | 463 | | 209 | ||
| | $ | 895 | | $ | 424 |
| | | | | | | | | | | | |
| | | | | | | | Non-Equity | | | | |
| | | | | | Option | | Incentive Plan | | All Other | | |
| | | | Salary | | Awards | | Compensation | | Compensation | | Total |
Name and Principal Position | Year | ($)(1) | ($)(2) | ($)(3) | ($)(4) | ($) | ||||||
Zhengbin (Bing) Yao, Ph.D. | | | | | | | | | | | | |
Chief Executive Officer and President | 2023 | 536,475 | | 394,693 | (5) | 241,414 | 13,200 | 1,185,782 | ||||
| | 2022 | 516,042 | | 413,091 | (5) | 258,021 | 12,200 | 1,199,354 | |||
Stuart Lutzker, M.D., Ph.D.(9) | | | | | | | | | | | | |
President of Research and Development | 2023 | 476,867 | | 119,326 | (6) | 219,359 | 13,200 | 828,752 | ||||
| | 2022 | 456,666 | | 114,071 | (6) | 182,667 | 1,400 | 754,804 | |||
Robin LaChapelle(10) | | | | | | | | | | | | |
Chief Operating Officer | | 2023 | 392,639 | | 374,533 | (8) | 180,614 | 13,200 | 960,986 | |||
| 2022 | (7) | 319,164 | | 73,648 | (8) | 127,667 | 10,858 | 531,337 |